- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07933627
Clinical Study of YKYY013 Injection in HBeAg-negative Chronic Hepatitis B Virus-infected Patients Treated With Nucleos(t)Ide Analogues
A Randomized, Double-blind, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of YKYY013 in Patients With HBeAg-negative Chronic Hepatitis B Virus Infection Treated With Nucleos(t)Ide Analogs
To evaluate the efficacy of YKYY013 in patients with chronic hepatitis B virus (HBV) infection with negative hepatitis B e antigen (HBeAg) and treated with nucleoside (acid) analogs (NA).
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
1)Evaluate the safety and tolerability of YKYY013 in patients with HBeAg-negative chronic HBV infection treated with NA; 2) Evaluate the pharmacokinetic (PK,with the serum drug concentration of YKYY013) and pharmacodynamic (PD,with reduction in HBsAg) characteristics of YKYY013 in patients with HBeAg-negative chronic HBV infection treated with NA; 3) Evaluate the immunogenicity of YKYY013 in patients with HBeAg-negative chronic HBV infection treated with NA.
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
- Name: Yuting Zhou
- Telefonnummer: +86 18606417018
- E-Mail: zhouyuting@bjykkc.com
Studienorte
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100050
- Beijing Friendship Hospital, affiliated with Capital Medical University
-
Kontakt:
- Jidong Jia
- Telefonnummer: +86-010-63139003
- E-Mail: jia_jd@ccmu.edu.cn
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Body Mass Index (BMI) between 18.0 to 32.0 kg/m^2 (inclusive) and body weight equal to or over 50 kg for male and 45 kg for female.
- Chronic HBV infection , with positive hepatitis B surface antigen (HBsAg) or HBV DNA for at least 6 months, and continuous stable treatment with a single nucleoside (acid) analogue (NA) for ≥ 6 months.
3)HBeAg-negative at screening; 4)100 IU/mL < HBsAg ≤ 5000 IU/mL at screening; 5)HBV DNA < 100 IU/mL at screening. 6) Medically approved contraception (e.g., intrauterine device, oral contraceptive, condom) during the trial and for 6 months after the last dose, Participants must not donate sperm or ova during the trial or for 6 months after the last dose.
7) The participants voluntarily participate in the study, and sign the Informed Consent Form (ICF) prior to screening.
Exclusion Criteria:
-
Severe allergic reactions, non-allergic drug reactions, multiple drug allergies, or known hypersensitivity to the investigational drug or its excipients.
-
Chronic liver disease other than chronic HBV infection (e.g., severe fatty liver, alcoholic, autoimmune, or inherited metabolic liver disease).
-
Liver stiffness measurement (LSM) above 9 kPa at screening, or Metavir F3 or higher on biopsy within 1 year before screening.
-
Current or past hepatic decompensation (e.g., esophagogastric variceal bleeding, ascites, hepatic encephalopathy).
-
Liver cancer history, or imaging (ultrasound, MRI, CT) suggesting liver cancer, or alpha-fetoprotein (AFP) at least 50 ug/L.
-
Cardiovascular events (e.g., stroke, transient ischemic attack, myocardial infarction, unstable angina, coronary bypass surgery, percutaneous coronary intervention, heart failure hospitalization) or clinically significant valvular heart disease. Other chronic diseases considered unsuitable by the investigator (e.g., respiratory, endocrine, immune, renal, hepatic, gastrointestinal, dermatologic, hematologic, neurologic).
-
Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage) or bleeding tendency (e.g., recurrent gingival bleeding); cured disease without active or clinically significant bleeding may be enrolled at investigator discretion.
-
Severe infection within 1 month, or infection symptoms within 7 days, before screening.
-
Major illness or major surgery (excluding minor outpatient procedures) within 3 months before screening, or planned grade 3-4 surgery during the trial.
-
Malignancy within 5 years, except cured resected in situ carcinoma (e.g., non-melanoma skin cancer).
-
Clinically significant abnormalities on physical examination, vital signs, 12-lead electrocardiogram (ECG), or chest CT at screening.
-
Uncontrolled blood pressure at screening (systolic at least 160 mmHg or diastolic at least 100 mmHg despite treatment).
-
Fridericia-corrected QT interval (QTcF) at least 450 msec (male) or 470 msec (female); if the first ECG exceeds these limits, two more ECGs are done and the mean of three applies.
-
Significant laboratory abnormalities at screening, including:
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) at least 2 times the upper limit of normal (ULN).
- Total bilirubin at least 2 times ULN with direct bilirubin above ULN.
- Serum albumin below 35 g/L.
- Platelets below 100 x 10^9/L.
- Prothrombin time (PT) prolonged by more than 3 seconds, international normalized ratio (INR) above 1.3, or clinically significant fibrinogen abnormality.
- Creatinine clearance (Cockcroft-Gault) 60 mL/min or less, or clinically significant proteinuria.
- Poorly controlled diabetes with glycated hemoglobin (HbA1c) above 7.0%.
-
AIDS, hepatitis A, B, C, or D, or positive screening for HIV antibody, Treponema pallidum antibody, or hepatitis A, B, C, or D antibody; positive hepatitis C antibody requires HCV RNA testing, and positive HCV RNA excludes.
-
Any potentially hepatotoxic drug (prescription, over-the-counter, or herbal) within 14 days (or 5 half-lives, if longer) before the first dose, if judged unsuitable by the investigator; stable therapy for hypertension or diabetes is allowed.
-
Interferon or immunosuppressant treatment within 12 months before screening, excluding short-term (2 weeks or less) use and topical or inhaled corticosteroids.
-
Live vaccine within 1 month before screening.
-
Small interfering RNA (siRNA) drug trial within 6 months, or other investigational drug within 3 months, before screening; or planned participation in another interventional trial.
-
Severe intolerance to subcutaneous injection (mild local reactions are acceptable).
-
Difficult venous access or venipuncture intolerance; history of syncope or hematophobia.
-
Pregnancy, lactation, or positive pregnancy test at screening or baseline.
-
Any scientific, compliance, or safety reason for which the investigator considers participation unsuitable.
-
Inability to communicate or cooperate due to neurologic or psychiatric disorder or language barrier.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: YKYY013
Drug: YKYY013 Injection Administration method: Administer subcutaneous injections according to the dose groups A/B/C/D every 4 weeks until the 48th week. |
Drug: YKYY013 Injection Administration method: Administer subcutaneous injections according to the dose groups A/B/C/D every 4 weeks until the 48th week. |
|
Placebo-Komparator: YKYY013 Placebo
Drug: 0.9% Sodium Chloride Injection Administration method: Administer subcutaneous injections according to the dose groups A/B/C/D every 4 weeks until the 48th week. |
Drug: 0.9% Sodium Chloride Injection Administration method: Administer subcutaneous injections according to the dose groups A/B/C/D every 4 weeks until the 48th week. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
The proportion (percent) of participants who achieved serum HBsAg < LLOQ (0.05 IU/mL) and HBVDNA < LLOQ at the 24th week
Zeitfenster: Week 24
|
Week 24
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
The proportion (percent) of trial participants who maintained sustained efficacy during the 24-week period after discontinuation of YKYY013 (the NA monotherapy period, up to W72) after completing the YKYY013 treatment course.
Zeitfenster: Week 72
|
Week 72
|
|
The proportion (percent) of participants who achieved serum HBsAg < LLOQ (0.05 IU/mL) and HBV DNA < LLOQ at the end of YKYY013 treatment.
Zeitfenster: Week 48
|
Week 48
|
|
The proportion (percent) of trial participants who met the NA drug discontinuation criteria and stopped all chronic hepatitis B treatments (YKYY013 and NA drugs) and maintained sustained efficacy during a 24-week period.
Zeitfenster: Week 72,Week 96
|
Week 72,Week 96
|
|
The proportion (percent) of trial participants who met the discontinuation criteria for NA treatment at the 72nd week
Zeitfenster: Week 72
|
Week 72
|
|
Compared to the baseline level, the percentage (percent) of participants in the HBsAg test at different levels was reduced (e.g., ≥0.5, ≥1, ≥1.5, ≥2.0, ≥3 log10 IU/mL);
Zeitfenster: From the first day to the 96th week
|
From the first day to the 96th week
|
|
The detection values (IU/mL) of HBsAg;
Zeitfenster: From the first day to the 96th week
|
From the first day to the 96th week
|
|
The maximum reductions (IU/mL) of HBsAg from the baseline;
Zeitfenster: From the first day to the 96th week
|
From the first day to the 96th week
|
|
The relative changes (IU/mL)of HBsAg from the baseline;
Zeitfenster: From the first day to the 96th week
|
From the first day to the 96th week
|
|
The detection values (copies/ml) of HBV RNA;
Zeitfenster: From the first day to the 96th week
|
From the first day to the 96th week
|
|
The maximum reductions (copies/ml) of HBV RNA from the baseline;
Zeitfenster: From the first day to the 96th week
|
From the first day to the 96th week
|
|
The relative changes (copies/ml) of HBV RNA from the baseline;
Zeitfenster: From the first day to the 96th week
|
From the first day to the 96th week
|
|
The detection values (U/mL) of HBcrAg;
Zeitfenster: From the first day to the 96th week
|
From the first day to the 96th week
|
|
The maximum reductions (U/mL) of HBcrAg from the baseline;
Zeitfenster: From the first day to the 96th week
|
From the first day to the 96th week
|
|
The relative changes (U/mL) of HBcrAg from the baseline;
Zeitfenster: From the first day to the 96th week
|
From the first day to the 96th week
|
|
The detection values (IU/mL) of HBV DNA;
Zeitfenster: From the first day to the 96th week
|
From the first day to the 96th week
|
|
The maximum reductions (IU/mL) of HBV DNA from the baseline;
Zeitfenster: From the first day to the 96th week
|
From the first day to the 96th week
|
|
The relative changes (IU/mL) of HBV DNA from the baseline;
Zeitfenster: From the first day to the 96th week
|
From the first day to the 96th week
|
|
The number and percentage (percent) of trial participants whose HBsAg and/or HBV DNA levels have dropped below the quantitative limit;
Zeitfenster: From the first day to the 96th week
|
From the first day to the 96th week
|
|
The number and percentage (percent) of trial participants whose highly sensitive HBsAg (LLOQ ≤ 0.005 IU/mL) decreased below the quantitative limit;
Zeitfenster: From the first day to the 96th week
|
From the first day to the 96th week
|
|
The positive rate (percent) and detection concentration (IU/L) of hepatitis B virus surface antibody (HBsAb);
Zeitfenster: From the first day to the 96th week
|
From the first day to the 96th week
|
|
The positive rate (percent) of hepatitis B virus e antibody (HBeAb).
Zeitfenster: From the first day to the 96th week
|
From the first day to the 96th week
|
|
Adverse events during treatment (TEAE)
Zeitfenster: From the first day to the 96th week
|
From the first day to the 96th week
|
|
Number of participants with abnormally elevated body temperature.
Zeitfenster: From the first day to the 96th week
|
From the first day to the 96th week
|
|
Number of participants with reactions at the injection site from prior administration.
Zeitfenster: From the first day to the 96th week
|
From the first day to the 96th week
|
|
Number of participants with abnormal time between the start of the q wave and the end of the t wave (QT/QTc interval) on 12-lead electrocardiogram (ECG).
Zeitfenster: From the first day to the 96th week
|
From the first day to the 96th week
|
|
Number of participants with liver function abnormalities during the treatment period.
Zeitfenster: From the first day to the 96th week
|
From the first day to the 96th week
|
|
The number and proportion of participants with positive anti-drug antibodies (ADA).
Zeitfenster: Day 1, Day 169, Day 337, Day 505, Day 673, or Early Termination; sampling time windows consistent with visit windows; pre-dose on dosing days
|
Day 1, Day 169, Day 337, Day 505, Day 673, or Early Termination; sampling time windows consistent with visit windows; pre-dose on dosing days
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- CLSP-YKYY013-Z02
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .